Stocks TelegraphStocks Telegraph
Stock Ideas

GENB Financial Statements and Analysis

NASDAQ : GENB

Generate Biomedicines

$15.18
0.805+5.60%
Open: 12:45 PM

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateMar 31, 2026
reported currencyUSD
calendar year2026
periodQ1
revenue7.224M
cost of revenue3.273M
gross profit3.951M
gross profit ratio0.547
research and development expenses54.561M
general and administrative expenses0
selling and marketing expenses0
selling general and administrative expenses13.502M
other expenses0
operating expenses68.063M
cost and expenses71.336M
interest income2.913M
interest expense182.00K
depreciation and amortization3.273M
ebitda-60.839M
ebitda ratio-8.422
operating income-64.112M
operating income ratio-8.875
total other income expenses net2.426M
income before tax-61.686M
income before tax ratio-8.539
income tax expense28.00K
net income-61.446M
net income ratio-8.506
eps-0.54
eps diluted-0.54
weighted average shs out128.192M
weighted average shs out dil128.192M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateMar 31, 2026
reported currencyUSD
calendar year2026
periodQ1
cash and cash equivalents160.575M
short term investments356.066M
cash and short term investments516.641M
net receivables0
inventory0
other current assets18.749M
total current assets535.39M
property plant equipment net85.602M
goodwill0
intangible assets0
goodwill and intangible assets0
long term investments0
tax assets0
other non current assets4.745M
total non current assets90.347M
other assets0
total assets625.737M
account payables7.617M
short term debt14.261M
tax payables0
deferred revenue17.244M
other current liabilities19.267M
total current liabilities58.389M
long term debt51.309M
deferred revenue non current1.238M
deferred tax liabilities non current0
other non current liabilities0
total non current liabilities52.547M
other liabilities0
capital lease obligations0
total liabilities110.936M
preferred stock0
common stock128.00K
retained earnings-737.739M
accumulated other comprehensive income loss24.00K
other total stockholders equity1.252B
total stockholders equity514.801M
total equity514.801M
total liabilities and stockholders equity625.737M
minority interest0
total investments356.066M
total debt65.57M
net debt-95.005M
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateMar 31, 2026
reported currencyUSD
calendar year2026
periodQ1
deferred income tax0
stock based compensation0
change in working capital-30.653M
accounts receivables0
inventory0
accounts payables3.754M
other working capital-34.407M
other non cash items8.438M
net cash provided by operating activities-80.388M
investments in property plant and equipment-3.781M
acquisitions net7.50M
purchases of investments-321.153M
sales maturities of investments65.00M
other investing activites0
net cash used for investing activites-252.434M
debt repayment-1.115M
common stock issued372.506M
common stock repurchased0
dividends paid0
other financing activites0
net cash used provided by financing activities371.391M
effect of forex changes on cash122.006M
net change in cash160.575M
cash at end of period160.575M
cash at beginning of period0
operating cashflow-80.388M
capital expenditure-3.781M
free cash flow-84.169M
Graph

Frequently Asked Questions

How did Generate Biomedicines, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, GENB generated $7.22M in revenue last quarter, while its costs came in at $3.27M.
Last quarter, how much Gross Profit did Generate Biomedicines, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Generate Biomedicines, Inc. reported a $3.95M Gross Profit for the quarter ended Mar 31, 2026.
Have GENB's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. GENB incurred $68.06M worth of Operating Expenses, while it generated -$64.11M worth of Operating Income.
How much Net Income has GENB posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Generate Biomedicines, Inc., the company generated -$61.45M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Generate Biomedicines, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Generate Biomedicines, Inc. as of the end of the last quarter was $160.58M.
What are GENB's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, GENB had Total Net Receivables of $0.00.
In terms of Total Assets and Current Assets, where did Generate Biomedicines, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of GENB were $535.39M, while the Total Assets stand at $625.74M.
As of the last quarter, how much Total Debt did Generate Biomedicines, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of GENB's debt was $65.57M at the end of the last quarter.
What were GENB's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, GENB reported total liabilities of $110.94M.
How much did GENB's Working Capital change over the last quarter?
Working Capital Change for GENB was -$30.65M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
GENB generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. GENB generated -$80.39M of Cash from Operating Activities during its recently reported quarter.
What was GENB's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. GENB reported a $160.58M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph